Arcadia Biosciences (RKDA) Liabilities and Shareholders Equity (2014 - 2025)

Arcadia Biosciences has reported Liabilities and Shareholders Equity for 12 years, with the latest figure at $6.5 million in Q4 2025.

• For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 51.57% year-over-year to $6.5 million; the trailing twelve-month figure through Dec 2025 stood at $35.9 million (down 42.25% YoY), and the FY2025 full-year result was $6.5 million, down 51.57% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $6.5 million, down from $8.6 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $70.8 million in Q1 2021, with the low at $6.5 million in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $29.0 million across 5 years, with a median of $25.1 million in 2023.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity soared 119.55% — and 2025, when it slumped 55.16%.
• Arcadia Biosciences' Liabilities and Shareholders Equity stood at $43.9 million in 2021, then sank by 34.15% to $28.9 million in 2022, then tumbled by 31.87% to $19.7 million in 2023, then sank by 31.4% to $13.5 million in 2024, then sank by 51.57% to $6.5 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $6.5 million (Q4 2025), $8.6 million (Q3 2025), and $7.8 million (Q2 2025), per Business Quant data.